(4,5-dihydro-oxazol-2-yl)-phenethyl-amine | 91180-77-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4,5-dihydro-oxazol-2-yl)-phenethyl-amine
• 英文别名: (4,5-Dihydro-oxazol-2-yl)-phenaethyl-amin；2-(Phenethylamino)-2-oxazoline；N-(2-phenylethyl)-4,5-dihydro-1,3-oxazol-2-amine
• CAS: 91180-77-7
• 化学式: C₁₁H₁₄N₂O
• 分子量: 190.245
• InChiKey: DEHMNHUFKPSTFA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  33.6
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Insecticidal Substituted Benzylamino Heterocyclic and Heteroaryl Derivatives
  申请人：Dixson John A.

  公开号：US20090036306A1

  公开（公告）日：2009-02-05

  Certain substituted benzylamino heterocyclic and heteroaryl derivatives have provided unexpected insecticidal and acaricidal activity. These compounds are represented by formula (1): wherein R, R1, R2, R3, and R4 are fully described herein. In addition, compositions comprising an insecticidally effective amount of at least one compound of formula (1), and optionally, an effective amount of at least one of an additional compound, with at least one insecticidally compatible carrier are also disclosed; along with methods of controlling insects comprising applying said compositions to a locus where insects are present or are expected to be present.

  某些取代苯基氨基的杂环和杂环芳基衍生物具有出乎意料的杀虫和杀螨活性。这些化合物由公式(1)表示:其中R、R1、R2、R3和R4在此完整描述。此外，还公开了包含公式(1)中至少一种化合物的杀虫有效量的组合物，以及可选地，至少一种附加化合物的有效量，与至少一种杀虫兼容载体的组合物;以及控制昆虫的方法，包括将所述组合物应用于昆虫存在或预计存在的地点。
• Agents for reversing toxic proteinopathies
  申请人：THE BROAD INSTITUTE, INC.

  公开号：US11207278B2

  公开（公告）日：2021-12-28

  The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of proteinopathies, particularly MUC1-associated kidney disease (ADTKD-MUC1 or MKD), Retinitis Pigmentosa (e.g., due to rhodopsin mutations), autosomal dominant tubulo-interstitial kidney disease due to UMOD mutation(s) (ADTKD-UMOD), and other forms of toxic proteinopathies resulting from mutant protein accumulation in the ER or other secretory pathway compartments and/or vesicles, among others. The disclosure also identifies and provides TMED9-binding agents as capable of treating or preventing proteinopathies of the secretory pathway, and further provides methods for identifying additional TMED9-binding agents.

  本公开涉及用于诊断和治疗或预防蛋白病的组合物和方法，特别是MUC1相关性肾病（ADTKD-MUC1或MKD）、视网膜色素变性（例如，由于视网膜色素变性导致的视网膜色素变性）、由于UMOD突变导致的常染色体显性肾小管间质性肾病（ADTKD-UMOD）以及其他形式的毒性蛋白病、由于 UMOD 突变引起的常染色体显性肾小管间质性肾病（ADTKD-UMOD），以及由于突变蛋白在 ER 或其他分泌途径区室和/或囊泡中积累而导致的其他形式的毒性蛋白病等。本公开还确定并提供了能够治疗或预防分泌途径蛋白病的 TMED9 结合剂，并进一步提供了确定其他 TMED9 结合剂的方法。
• INSECTICIDAL SUBSTITUTED BENZYLAMINO HETEROCYCLIC AND HETEROARYL DERIVATIVES
  申请人：Bayer CropScience AG

  公开号：EP1885180A2

  公开（公告）日：2008-02-13
• AGENTS FOR REVERSING TOXIC PROTEINOPATHIES
  申请人：THE BROAD INSTITUTE, INC.

  公开号：US20210169827A1

  公开（公告）日：2021-06-10

  The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of proteinopathies, particularly MUC1-associated kidney disease (ADTKD-MUC1 or MKD), Retinitis Pigmentosa (e.g., due to rhodopsin mutations), autosomal dominant tubulo-interstitial kidney disease due to UMOD mutation(s) (ADTKD-UMOD), and other forms of toxic proteinopathies resulting from mutant protein accumulation in the ER or other secretory pathway compartments and/or vesicles, among others. The disclosure also identifies and provides TMED9-binding agents as capable of treating or preventing proteinopathies of the secretory pathway, and further provides methods for identifying additional TMED9-binding agents.
• US8193118B2
  申请人：——

  公开号：US8193118B2

  公开（公告）日：2012-06-05